Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (121-130 of 336) with videos related to

Pageof 34
Sort By:
Scientific Reports|February 7, 2020
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patientsSebastiano Buti, Pierre I Karakiewicz, Melissa Bersanelli, et al.
Current Oncology Reports|December 23, 2025
Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune RegulationValentina Santo, Leonardo Brunetti, Federica Pecci, et al.
Cancer Medicine|January 2, 2024
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetateOndřej Fiala, Petr Hošek, Hana Korunková, et al.
Communications Medicine|May 27, 2026
Microplastics as both a driver of genitourinary cancers and a deliverer of treatmentsKannan Sridharan, Brigida Anna Maiorano, Farah Rehan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)Marcello Tiseo, Angela Damato, Lucia Longo, et al.
Plos One|February 28, 2017
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Satoru Taguchi, Sebastiano Buti, Hiroshi Fukuhara, et al.
The Oncologist|February 15, 2026
A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trialSebastiano Buti, Se-Eun Kim, Michele Maffezzoli, et al.
Clinical Genitourinary Cancer|January 31, 2024
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or PazopanibMartina Catalano, Ugo De Giorgi, Davide Bimbatti, et al.
Tumori|September 29, 2021
Transient asymptomatic pulmonary opacities and interstitial lung disease in <i>EGFR</i>-mutated non-small cell lung cancer treated with osimertinibGianluca Taronna, Alessandro Leonetti, Filippo Gustavo Dall'Olio, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Pageof 34

Showing results (121-130 of 336) with videos related to

Sort By:
Pageof 34
Scientific Reports|February 7, 2020
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patientsSebastiano Buti, Pierre I Karakiewicz, Melissa Bersanelli, et al.
Current Oncology Reports|December 23, 2025
Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune RegulationValentina Santo, Leonardo Brunetti, Federica Pecci, et al.
Cancer Medicine|January 2, 2024
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetateOndřej Fiala, Petr Hošek, Hana Korunková, et al.
Communications Medicine|May 27, 2026
Microplastics as both a driver of genitourinary cancers and a deliverer of treatmentsKannan Sridharan, Brigida Anna Maiorano, Farah Rehan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)Marcello Tiseo, Angela Damato, Lucia Longo, et al.
Plos One|February 28, 2017
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Satoru Taguchi, Sebastiano Buti, Hiroshi Fukuhara, et al.
The Oncologist|February 15, 2026
A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trialSebastiano Buti, Se-Eun Kim, Michele Maffezzoli, et al.
Clinical Genitourinary Cancer|January 31, 2024
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or PazopanibMartina Catalano, Ugo De Giorgi, Davide Bimbatti, et al.
Tumori|September 29, 2021
Transient asymptomatic pulmonary opacities and interstitial lung disease in <i>EGFR</i>-mutated non-small cell lung cancer treated with osimertinibGianluca Taronna, Alessandro Leonetti, Filippo Gustavo Dall'Olio, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Pageof 34